CDA | Evidence Driven
CDA | Evidence Driven

Enzalutamide (Xtandi) for Metastatic Castration Sensitive Prostate Cancer - Details

Details

Files
Generic Name:
Enzalutamide
Project Status:
Complete
Therapeutic Area:
mHSPC
Manufacturer:
Astellas Pharma Canada, Inc.
Brand Name:
Xtandi
Project Line:
Reimbursement Review
Project Number:
PC0209-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
40mg
Tumour Type:
Genitourinary
Indications:
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Funding Request:
For the treatment of patients with metastatic castration sensitive prostate cancer
Pre Noc Submission:
Yes
Sponsor:
Astellas Pharma Canada, Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Enzalutamide (Xtandi) mCSPC – pERC Final Recommendation Final Recommendation September 23, 2020 View PDF
Enzalutamide (Xtandi) mCSPC – Final Economic Guidance Report Guidance Report September 23, 2020 View PDF
Enzalutamide (Xtandi) mCSPC – Final Clinical Guidance Report Guidance Report September 23, 2020 View PDF
Enzalutamide (Xtandi) mCSPC – pERC Initial Recommendation Initial Recommendation September 3, 2020 View PDF
Enzalutamide (Xtandi) mCSPC – PAG Feedback on Initial Recommendation Feedback September 23, 2020 View PDF
Enzalutamide (Xtandi) mCSPC – Manufacturer Feedback on Initial Recommendation Feedback September 23, 2020 View PDF
Enzalutamide (Xtandi) mCSPC – Clinician Feedback on Initial Recommendation Feedback September 23, 2020 View PDF
Enzalutamide (Xtandi) mCSPC – Patient Advocacy Group COI Declarations COI Declarations September 23, 2020 View PDF
Enzalutamide (Xtandi) mCSPC – PAG Feedback on Initial Recommendation - Feedback View PDF
Enzalutamide (Xtandi) mCSPC – Clinician COI Declarations View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : October 8, 2020